Merck press release
RAHWAY, N.J., April 21, 2026 — Merck, known as MSD outside of the United States and Canada, announced today that the US Food and Drug Administration (FDA) approved IDVYNSO™ (pronounced ihd-VIHN-soh), a new, two-drug single-tablet regimen of 100 mg doravirine and 0.25 mg islatravir, for the treatment of HIV-1 infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no history of virologic treatment failure and no known substitutions associated with resistance to doravirine. IDVYNSO is contraindicated when co-administered with drugs that are strong cytochrome P450 (CYP)3A enzyme inducers and lamivudine or emtricitabine. Co-administration with these drugs may decrease the effectiveness of IDVYNSO.
IDVYNSO is the first and only non-INSTI, tenofovir-free, once-daily, complete two-drug regimen to demonstrate non-inferior efficacy in a head-to-head Phase 3 trial versus three-drug regimen BIKTARVY®i (BIC/FTC/TAF).
Read the full press release here.
Source : Merck
Related HIV and Co-Infections News
-
ESCMID: HIV treatment reduces accelerated biological aging by nearly four years, landmark study shows
-
Infectious Disease Advisor: Real-world data support switch to doravirine-based ART: HIV-1 control and QOL
-
EL PAÍS: US aid cuts collapse Malawi’s LGBTQ+ health services as volunteers scramble to fill the void
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.